These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32623076)

  • 21. Advanced thymic lymphoepithelioma-like carcinoma with bone marrow metastases treated by immunotherapy combined with antiangiogenesis therapy: a case report.
    Li YJ; Li YW; Cui GH; Li SH; Deng YW; Lu D
    Anticancer Drugs; 2022 Aug; 33(7):686-690. PubMed ID: 35324515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for LELC: Case Report and a Focused Review.
    Darrason M; Martin A; Soussan M; Chouahnia K; Pailler MC; Boudabous H; Brillet PY; Bousquet G; Zelek L; Duchemann B
    Clin Lung Cancer; 2019 May; 20(3):e393-e401. PubMed ID: 30691964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study.
    Chen M; Chen Y; Fang X; Wang Z; Pu X; Liang C; Guo H; Li Q; Pan F; Hong H; Huang H; Li J; Lin T
    BMC Pulm Med; 2022 Sep; 22(1):360. PubMed ID: 36138362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma.
    Huang CJ; Feng AC; Fang YF; Ku WH; Chu NM; Yu CT; Liu CC; Lee MY; Hsu LH; Tsai SY; Shih CS; Wang CL
    Clin Lung Cancer; 2012 Sep; 13(5):359-62. PubMed ID: 22410385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
    Rounds A; Kolesar J
    Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma.
    Jiang L; Wang L; Li PF; Zhang XK; Chen JW; Qiu HJ; Wu XD; Zhang B
    Onco Targets Ther; 2015; 8():1451-7. PubMed ID: 26109869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.
    Senoo S; Ninomiya T; Makimoto G; Nishii K; Kano H; Watanabe H; Hata Y; Kubo T; Tanaka T; Hotta K; Maeda Y; Kiura K
    Intern Med; 2019 Apr; 58(7):985-989. PubMed ID: 30568113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience.
    Fu Y; Zheng Y; Wang PP; Chen YY; Ding ZY
    Onco Targets Ther; 2021; 14():1073-1081. PubMed ID: 33628032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
    Lim JS; Soo RA
    Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab plus ipilimumab in non-small-cell lung cancer.
    Reck M; Borghaei H; O'Byrne KJ
    Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoepithelioma-like carcinoma of the lung: a rare case report and review of the literature.
    Fırıncıoğluları A; Akıncı Özyürek B; Erdoğan Y; İncekara F; Yılmaz E; Özaydın HE
    Tuberk Toraks; 2020 Dec; 68(4):453-457. PubMed ID: 33448744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report.
    Zeng SY; Yuan J; Lv M
    World J Clin Cases; 2022 Nov; 10(31):11617-11624. PubMed ID: 36387802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
    Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
    Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
    Rebuzzi SE; Leonetti A; Tiseo M; Facchinetti F
    Immunotherapy; 2019 Aug; 11(12):993-1003. PubMed ID: 31319742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.